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Using an antibody generated against he opiate receptor on NG 108-15 cells, we recently purified the putative 
receptor from this hybrid cell line. We herein report hat the purified receptor complex specifically binds 
tritiated cis-(+)-3-methylfentanylisothiocyanate (SUPERFIT), with the predominant binding associated 
with a 58 kDa polypeptide chain. Consistent with these findings is the in situ labeling of a 58 kDa protein 
with [aH]SUPERFIT on NG108-15 cells. 
Complementary peptide; cis-(+)-3-Methylfentanylisothiocyanate; Opiate receptor 
1. INTRODUCTION 
Opiate receptor heterogeneity has, for the most 
part, complicated the isolation and characteriza- 
tion procedures of the receptor complex. However, 
with the advent of highly specific opiate receptor 
ligands, it has become possible to identify binding 
subunits of the receptor(s) on various tissues. One 
such ligand, cis-(+)-3-methylfentanylisothiocya- 
nate (SUPERFIT) [1] has been used to isolate the 
binding polypeptide chain of the ~-class opiate 
receptor from the neuroblastoma x glioma hybrid 
cell line, NG108-15 [2]. The apparent molecular 
mass of this binding protein, 58 kDa, is in agree- 
ment with what other investigators have observed 
[3,4]. Although it is evident hat the predominant 
binding chain of the 8-class opiate receptor is the 
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58 kDa polypeptide chain, other chains which are 
not responsible for recognition of ligands but have 
other intrinsic values to the receptor complex 
would not necessarily be isolated by this pro- 
cedure. However, by making an antibody to the 
receptor complex, it would be possible to isolate all 
the constituents of the complex and determine 
which chain(s) is(are) responsible for ligand recog- 
nition. 
Recently, we have developed an antibody to the 
opiate receptor complex from NG108-15 cells [5] 
by the use of the complementary peptide 
methodology [6]. This methodology is based on 
the Molecular Recognition Theory which states 
that binding sites of interacting proteins can be en- 
coded by complementary strands of DNA and has 
been employed by ourselves and others [7,8] to in- 
vestigate ligand-receptor interactions. We reported 
that in addition to a 58 kDa polypeptide (pertain- 
ing to the opiate receptor) not unlike that described 
by others, we isolated three other polypeptide 
chains (68, 45, 30 kDa) which appeared to be non- 
Published by Elsevier Science Publishers B.V. (Biomedical Division) 
272 00145793/87/$3.50 © 1987 Federation ofEuropean Biochemical Societies 
Volume 224, number 2 FEBS LETTERS November 1987 
covalently associated. In order to determine if the 
immunoaffinity purified receptor still possessed 
opiate-specific characteristics a well as to deter- 
mine the binding chain, we employed SUPERFIT. 
2. MATERIALS AND METHODS 
2.1. Crosslinking cell surface proteins in 
NG108-15 cells 
The crosslinking procedure used has been 
previously described [9]. Briefly, 5 × 107 
NG108-15 cells were pelleted and the reducible 
homobifunctional crosslinker, dithiobisphenyla- 
zide (Sigma, St. Louis, MO) was added to a final 
concentration of 15 mM in PBS-1.0% dimethyl 
sulfoxide (DMSO) at 4°C. The crosslinker was ac- 
tivated for 2 min using an ultraviolet light source 
(Ultraviolet Illuminator) with peak emission being 
350 nm. After irradiation, cells were washed in 
PBS and subsequently solubilized with lysis buffer 
which consists of 1.0°70 3-[3-cholamidopropyldi- 
methylammonio]- 1-propanesulfonate (CHAPS, 
Sigma)/0.5 M NaCI/0.1 mM phenylmethylsul- 
fonyl fluoride. 
2.2. Immunoaffinity chromatography of
NG108-15 cells 
The method for coupling ligands to CNBr- 
activated Sepharose 4B is as described in Phar- 
macia Fine Chemicals publication (affinity 
chromatography) (Uppsala). Dithiobisphenyla- 
zide-crosslinked NG108-15 cell lysates were spun 
at 700 × g for 10 min to remove cell debris. 
The supernatant fluid was added to phosphate- 
buffered saline (PBS)-0.05 M NaN3 (pH 7.4) at a 
1:6 volume ratio and passed over an anti-opiate 
receptor antibody affinity column. Material which 
bound to the column was eluted with PBS-0.05 M 
NaN3 (pH 2.0-2.5) and collected in 50 ml Falcon 
tubes (Fisher, Norcross, GA). The pH of the eluted 
solution was adjusted to 7.0 by the addition of 2 N 
NaOH. The material was then hydroextracted with 
polyethylene glycol (molecular mass range 15-20 
kDa) in dialysis tubing (molecular mass cutoff 
12-14 kDa, Fisher, Norcross, GA). Material was 
subsequently analyzed by polyacrylamide g l elec- 
trophoresis. 
2.3. In situ labeling of  NGl08-15 opiate receptor 
Approx. 1 x l0 T cells/ml in 0.05 M K2HPO4 
(pH 8.0) were incubated with cis-(+)-3-[3H] - 
methylfentanylisothiocyanate (SUPERFIT) (1.02 
/zM, spec. act. 7.85 Ci/mmol) in the presence or 
absence of unlabeled SUPERFIT (0.11 mM) for 
45 min at 37°C with agitation every 10 min. Cells 
were centrifuged for 5 min (200 × g) and lysed in 
denaturing buffer (0.062 M Tris-HC1, 2°70 SDS, 
10o70 glycerol, 5°70 2-mercaptoethanol, 0.001°70 
bromophenol b ue) for 5 min. Samples were then 
boiled for 3 min and analyzed by electrophoresis 
on a 10°70 polyacrylamide g l. Gels were then dried 
and subjected to autoradiography (10 days). 
2.4. Specific opiate binding of f H]SUPERFIT by 
crosslinked, immunoaffinity-purified 
receptor 
Crosslinked, immunoaffinity-purified NG108- 
15 (40/zg) receptor was incubated with [3H]- 
SUPERFIT (1.02/~M) in the presence or absence 
of unlabeled SUPERFIT (0.20 mM) or morphine 
(1.9 mM) at 37°C for 30 rain in 0.05 M KzHPO4 
(pH 8.0) containing 5/~g/ml bacitracin. The 
resulting sample was dialyzed for 18 h in running 
buffer to remove free [3H]SUPERFIT and hydro- 
extracted with polyethylene glycol. This material 
was electrophoresed on 10°70 polyacrylamide g ls 
under reducing (0.5 M 2-mercaptoethanol) c ndi- 
tions. The fixed, dried gel was subjected to 
autoradiography (10-14 days). 
2.5. Polyacrylamide gel electrophoresis of 
purified receptor 
The discontinuous buffer system of Laemmli 
[10] was used for electrophoresis of proteins on 
SDS-polyacrylamide gels containing 10070 
acrylamide. Samples were boiled for 3 min in 2% 
SDS, 0.062 M Tris-HC1, 10°70 glycerol, 5°70 
2-mercaptoethanol, and 0.001070 bromophenol 
blue and applied to a 5°70 polyacrylamide stacking 
gel. Electrophoresis was carried out at a constant 
current of 25 mA for 4-5 h. After electrophoresis, 
the gels were fixed in 40070 methanol-10% acetic 
acid and dried. Prestained molecular mass stan- 
dards [myosin (200000), phosphorylase b (97400), 
bovine serum albumin (68000), ovalbumin 
(43 000), cr-chymotrypsinogen (25 700), /3- 
lactoglobulin (18400), and lysozyme (14300)] 
(Bethesda Research Laboratories, Gaithersburg, 
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MD) were run with each gel to generate a plot of 
log Mr VS e f  for determination of the Mr of the 
radiolabeled protein species. 
3. RESULTS 
3.1. Purified receptor from NG108-15 cells 
specifically binds SUPERFIT 
Our previous results suggested that the anti- 
receptor antibody could recognize the opiate recep- 
tor complex from NG108-15 lysates. Since we had 
previously shown that the receptor was composed 
of more than one polypeptide chain, we sought o 
determine which polypeptide chain or chains were 
associated with the binding site. NG108-15 cells 
were in situ labeled with [3H]SUPERFIT in the 
presence or absence of unlabeled SUPERFIT. 
Labeled cells were lysed and the lysates were sub- 
jected to polyacrylamide gel electrophoresis. The 
resulting gel was dried and specific binding of the 
ligand was determined by autoradiography of the 
gel. The results (fig.lA) indicate that the 58 kDa 
chain of the opiate receptor is responsible for the 
recognition of SUPERFIT. Furthermore, the 
binding is specific since unlabeled SUPERFIT 
competed with labeled SUPERFIT (fig. 1B). The 
results we obtained confirm previous observations 
[2,3]. 
In order to determine whether immunoaffinity- 
purified receptor had the same characteristics once 
isolated from the NG108-15 cells, the above pro- 
cedure was conducted on such purified material. 
Thus, cell surface proteins from NG108-15 cells 
were crosslinked with the reducible crosslinker, 
dithiobisphenylazide as in [51 and the putative 
opiate receptor was purified by immunoaffinity 
chromatography. Isolated receptor was then in- 
cubated with [3H]SUPERFIT in the presence or 
absence of nonlabeled SUPERFIT or morphine (u- 
receptor ligand). The resulting material was 
analyzed by electrophoresis on polyacrylamide g ls 
and the resultant gels were dried and subjected to 
autoradiography to determine which chain(s) 
was(were) responsible for the recognition of 
SUPERFIT. The results (fig.2) indicate that the 
58 kDa chain is the major binding chain of the 8- 
class opiate receptor from NG108-15 cells. In addi- 
tion, some radioactivity was also associated with 
the 30 kDa polypeptide chain in a relatively 
specific manner. 
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Fig.1. [3H]SUPERFIT-labeled opiate receptor from 
NG108-15 neuroblastoma × glioma hybrid cells. 
Autoradiogram of a 10°70, reduced (2-mercaptoethanol) 
polyacrylamide gel exposed for 10 days. (A) 
[3H]SUPERFIT-labeled NG108-15 cells, (B) [3H]- 
SUPERFIT-labeled NG108-15 cells in the presence of 
excess unlabeled SUPERFIT. 
In order to establish whether it was necessary to 
crosslink the receptor complex prior to immunoaf- 
finity chromatography to maintain the integrity of 
the receptor and its binding chain, noncrosslinked 
purified opiate receptor was analyzed for its ability 
to bind the ligand, SUPERFIT. The results (not 
shown) indicate that like crosslinked, purified 
receptor, noncrosslinked, purified receptor had the 
capability of binding SUPERFIT with specificity 
although the efficiency of binding was less 
(20-30°7o). This strongly suggests a role for the in- 
tact receptor complex with regard to maximal 
binding capacity. 
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Fig.2. Autoradiography of electrophoresed, immuno- 
affinity-purified [3H]SUPERFIT-Iabeled opiate recep- 
tors from NG108-15 cells. Crosslinked (DTBP) immuno- 
affinity-purified receptors (40/~g) were incubated with 
1.02/~M [3H]SUPERFIT in the presence or absence of 
unlabeled SUPERFIT (2 x 10 -4 M) or morphine (1.9 × 
10 -3 M) for 45 min in 0.05 M K2HPO4 (pH 8.0). The 
resultant material was dialyzed overnight in phosphate- 
buffered saline (pH 7.4) to remove free radiolabeled 
ligand. Samples were hydroextracted with polyethylene 
glycol and applied to polyacrylamide g l electrophoresis. 
The resultant gels were dried and subjected to auto- 
radiography for 96 h. (A) Labeled SUPERFIT only, (B) 
lane A + morphine, (C) lane A + SUPERFIT. 
4. DISCUSSION 
We had previously reported the purification of 
the opiate receptor from NG108-15 cells to ap- 
parent homogeneity with an antibody to the opiate 
receptor [5] developed by the application of the 
complementary peptide approach [6]. In that 
report, we demonstrated the ability of the antibody 
to compete for the same binding site as ~'- 
endorphin on NG108-15 cells by a radioreceptor 
assay and ELISA procedure. In addition, our data 
indicated that the receptor was a complex com- 
posed of four polypeptide chains with molecular 
masses of 68, 58, 45, and 30 kDa. In order to 
establish further that we had isolated the putative 
opiate receptor from NG108-15 cells, we determin- 
ed whether purified receptor had the ability to 
recognize and bind the d-class opiate ligand, 
SUPERFIT. The results indicate the purified 
receptor bound SUPERFIT with specificity and 
furthermore, the predominate binding polypeptide 
chain had a molecular mass of 58 kDa. That the 
58 kDa chain of the immunoaffinity-purified 
receptor is the major binding subunit of the opiate 
receptor tends to confirm the in situ labeling of 
NG108-15 cells we (this work) and others [2,3] 
have observed. 
In addition to the specific labeling of the 58 kDa 
protein subunit of the crosslinked, purified 
material, we also observed the labeling of a 30 kDa 
protein. That this protein is not labeled in situ sug- 
gests that the crosslinking procedure draws the 
30 kDa chain in close enough proximity to the 
58 kDa protein that it too is labeled with SUPER- 
FIT in a specific manner. Therefore, we believe the 
labeling of this band is an experimental rtifact but 
relatively important in that it suggests the 30 kDa 
chain is closely associated with the binding chain. 
In addition to the 58 and 30 kDa proteins, we 
have also reported that the receptor consists of 68 
and 45 kDa protein chains. Although we do not 
know the function of these subunits, they may play 
a role in binding other ligands or in mediating 
secondary events (i.e. phosphorylation or (de)ac- 
tivation of secondary messengers). Other in- 
vestigators have reported opiate-binding proteins 
with similar molecular masses. For example, in 
30°70 purified preparations of an opiate receptor- 
fentanylisothiocyanate (FIT) complex from 
NG108-15 cells recognized by an anti-FIT im- 
munoglobulin, observation of 45 and 31 kDa pro- 
teins was described [3]. In addition, using an 
avidin-biotin system, other investigators have 
reported the purification of the d-class opiate 
receptor to consist of proteins of 58, 65, and 
71 kDa [11]. Recently, the demonstration of a 
46 kDa protein to be common to all opiate recep- 
tor classes [12] (including/~, g, and d;) along with 
reports by others [13-18] suggesting that the 
opiate receptor(s) consist(s) of proteins ranging in 
molecular mass from 70 to 23 kDa, seems to in- 
dicate the probability that more than one consti- 
tuent is associated with the opiate receptor binding 
chain and/or subunit structure. 
Our results using morphine to block SUPERFIT 
binding to the receptor suggest that /~-specific 
ligands may recognize the same binding chain as 
the d;-specific ligand, but interact with a different 
portion. This hypothesis i  not without precedent 
since it has recently been demonstrated that the/z- 
type opiate receptor binding site has an apparent 
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molecular mass of 58 kDa [19,20]. In addition, we 
suggest that crosslinked, purified receptor binds 
SUPERFIT more efficiently than noncrosslinked 
receptor. Such an observation may be due to the 
ability of the crosslinked complex to remain intact 
with its lipid moieties ince it is believed that lipid 
plays an important role in opiate binding [21,22]. 
Finally, our data seem to substantiate he results of 
other investigators working on opiate receptor 
purification. That our results are similar and in 
some cases, identical with those of others, seems to 
demonstrate the fidelity of the complementary 
peptide methodology and its application in ligand- 
receptor interactions. 
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